CIK cells from recurrent or refractory AML patients can be efficiently expanded in vitro and used for reduction of leukemic blasts in vivo

Wang, Yao; Jiang, Bo; Dai, Hanren; Lu, Xue-Chun; Lv, Haiyan; Yang, Bo; Wang, Tao; Han, Weidong

doi:10.1016/j.exphem.2012.10.014

Cited by 32 publications

(35 citation statements)

References 35 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…Leptin is known to stimulate breast cancer growth via cooperation with additional adipokinins such as hepatocyte growth factor. However, leptin can not only support the invasion of cancer cells, but also support the cancer growth indirectly by stimulation of abiogenesis [15] .…”

Section: Resultsmentioning

confidence: 99%

“…It is well established that strong deficit in iNKT cells can be a precondition to insufficient clinical effects of cancer treatment [11,13,15] . The percentage of these cells in total lymphocyte population is clearly negative prognostic factor [30] .…”

Section: Resultsmentioning

confidence: 99%

“…Expression of some inhibitory molecules results in inhibition of activity of cytotoxic T lymphocytes. Effector cells of natural immunity, such as NK cells, cytokine-induced killer cells CD3 + CD56 + CIK cells and gd T lymphocytes are extremely important, as they are not subject of MHC restriction and form the first line of anti-tumor surveillance [15] . These cells act as a bridge between natural and adaptive immunity and they share some common mechanisms including perforin-mediated toxicity and cytokine (STAT)-3 and expression of perforins and IL-2 genes [10] .…”

Section: Introductionmentioning

confidence: 99%

See 2 more Smart Citations

Reconstruction of NK Cells During Complex Cancer Treatment

et al. 2016

View full text Add to dashboard Cite

AIM:The role of glucan in potentiation of immune system is well established, including effects on cancer development. In this study, we focused on effects of short term glucan supplementation in patients during complex cancer treatment. MATERIALS AND METHODS:We measured the levels of leptin and changes in NK cell numbers after oral application of 200 mg/day of glucan. RESULTS: We found significant improvement in total numbers of NK cells. Levels of leptin remained unchanged. CONCLUSIONS: Our findings show the significant effects of glucan supplementation on induction of NK cell, suggesting that addition of glucan to the diet could be beneficial for prevention of cancer remission. The glucan-supplemented group exhibited some improvements in psychic conditions, nutritional state and overall feeling of well-being. Longer supplementation seems to be necessary.

show abstract

Section: Resultsmentioning

confidence: 99%

Section: Resultsmentioning

confidence: 99%

Section: Introductionmentioning

confidence: 99%

See 1 more Smart Citation

Reconstruction of NK Cells During Complex Cancer Treatment

et al. 2016

View full text Add to dashboard Cite

show abstract

“…Impressively, approximately 40% of patients attained disease control. Specific studies highlighting the clinical application of CIK infusion for AML include a report by Wang et al describing a patient with RR-AML who experienced a dramatic reduction in leukemic burden after four CIK infusions given over 4 months [44]. A more recent study evaluated the safety and feasibility of IL-15-activated CIK cells as a means of preventing relapse in high-risk leukemia [45].…”

Section: Cytokine-induced Killer Cellsmentioning

confidence: 99%

Advances in Immunotherapy for Acute Myeloid Leukemia

2018

View full text Add to dashboard Cite

Evasion of the host immune system is a key mechanism to promote malignant progression. Therapeutically targeting immune pathways has radically changed the treatment paradigm for solid and lymphoid tumors but has yet to be approved for myeloid malignancies. Here, we summarize the most recent advances in immunotherapy for acute myeloid leukemia. Topics reviewed here include adoptive cellular approaches (chimeric antigen receptor-T cells, natural killer and other immune cells), checkpoint inhibitors (anti-PD-1/PD-L1, anti-CTLA-4 and TIM-3) and vaccines (WT-1, HLA-A2 and hTERT). Emphasis is placed on agents with clear evidence of tumor-specific immune responses and/or clinical activity in early-phase trials. Despite concerns regarding heterogeneous antigen expression and cytokine release syndrome, immunotherapy remains a highly promising strategy for acute myeloid leukemia, particularly transplant-ineligible patients and minimal residual disease states.

show abstract

“…For example, chemotherapeutic agents or glucocorticoids were applied within one week of immune cell transfusion. Overall, fewer than 50 cases with integrated laboratory and clinical data were available for analysis (Yang et al, 2012;Lu et al, 2012;Wang et al, 2013;Sheng et al, 2009). Our five-year practice revealed that this CPC-centered and multidisciplinary collaborative translational approach provided a high-input, low-output model, at least under the current conditions of Chinese hospitals.…”

mentioning

confidence: 99%

Innovative and propagable translational research model established for cell-based therapy at Chinese PLA General Hospital

Han

2015

Sci. China Life Sci.

View full text Add to dashboard Cite

CIK cells from recurrent or refractory AML patients can be efficiently expanded in vitro and used for reduction of leukemic blasts in vivo

Cited by 32 publications

References 35 publications

Reconstruction of NK Cells During Complex Cancer Treatment

Reconstruction of NK Cells During Complex Cancer Treatment

Advances in Immunotherapy for Acute Myeloid Leukemia

Innovative and propagable translational research model established for cell-based therapy at Chinese PLA General Hospital

Contact Info

Product

Resources

About